Oruka Therapeutics (NASDAQ:ORKA) Trading 5% Higher Following Analyst Upgrade

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s share price traded up 5% on Tuesday after UBS Group raised their price target on the stock from $50.00 to $75.00. UBS Group currently has a buy rating on the stock. Oruka Therapeutics traded as high as $58.53 and last traded at $59.20. 623,149 shares were traded during mid-day trading, an increase of 7% from the average session volume of 584,512 shares. The stock had previously closed at $56.37.

ORKA has been the subject of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 16th. BTIG Research restated a “buy” rating and issued a $73.00 price target on shares of Oruka Therapeutics in a research note on Friday, March 13th. Guggenheim restated a “buy” rating and issued a $60.00 price target on shares of Oruka Therapeutics in a research note on Friday, March 13th. Finally, Stifel Nicolaus lifted their price target on Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $62.10.

Insider Activity at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,641 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $40.91, for a total transaction of $312,593.31. Following the transaction, the insider directly owned 33,377 shares in the company, valued at $1,365,453.07. The trade was a 18.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Lawrence Otto Klein sold 1,729 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the transaction, the chief executive officer owned 927,309 shares in the company, valued at approximately $38,297,861.70. This represents a 0.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 23,765 shares of company stock worth $849,575. Insiders own 24.69% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada lifted its holdings in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after acquiring an additional 365 shares during the last quarter. Kennedy Capital Management LLC lifted its holdings in Oruka Therapeutics by 0.9% in the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after acquiring an additional 420 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Oruka Therapeutics by 35.0% in the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after acquiring an additional 788 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Oruka Therapeutics by 62.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock valued at $71,000 after acquiring an additional 904 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in Oruka Therapeutics in the fourth quarter valued at approximately $37,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Price Performance

The stock has a market capitalization of $2.95 billion, a price-to-earnings ratio of -31.99 and a beta of -0.54. The business has a fifty day moving average of $37.40 and a 200 day moving average of $31.02.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.16. On average, equities research analysts expect that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.